Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia
Authors:
- Malia E. LeifheitMLMalia E. Leifheit
- Gunnar JohnsonGJGunnar Johnson
- Timothy M. KuzelTKTimothy M. Kuzel
- Jeffrey R. SchneiderJSJeffrey R. Schneider
- Edward BarkerEBEdward Barker
- Hyun D. YunHYHyun D. Yun
- Celalettin UstunCUCelalettin Ustun
- Josef W. GoldufskyJGJosef W. Goldufsky
- Kajal GuptaKGKajal Gupta
- Amanda L. MarzoAmanda L. Marzo
Open Access
- 30 August 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9448
Abstract
FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML represent a challenging clinical scenario characterized by a high rate of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The advent of FLT3 tyrosine kinase inhibitors (TKIs), such as midostaurin and gilteritinib, has shown promise in achieving complete remission. However, a substantial proportion of patients still experience relapse following TKI treatment, necessitating innovative therapeutic strategies. This review critically addresses the current landscape of TKI treatments for FLT3+ AML, with a particular focus on gilteritinib. Gilteritinib, a highly selective FLT3 inhibitor, has demonstrated efficacy in targeting the mutant FLT3 receptor, thereby inhibiting aberrant signaling pathways that drive leukemic proliferation. However, monotherapy with TKIs may not be sufficient to eradicate AML blasts. Specifically, we provide evidence for integrating gilteritinib with mammalian targets of rapamycin (mTOR) inhibitors and interleukin-15 (IL-15) complexes. The combination of gilteritinib, mTOR inhibitors, and IL-15 complexes presents a compelling strategy to enhance the eradication of AML blasts and enhance NK cell killing, offering a potential for improved patient outcomes.Keywords
Funding Information
- Rush University Department of Internal Medicine, Division of Hematology/Oncology (# 22-0803)
- Walder Foundation Innovation Top Up Award (# 22-0803)
This publication has 191 references indexed in Scilit:
- Update on Small Molecule Targeted Therapies for Acute Myeloid LeukemiaCurrent Treatment Options in Oncology, 2023
- FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta‐analysisCancer Medicine, 2022
- Which FLT3 Inhibitor for Treatment of AML?Current Treatment Options in Oncology, 2022
- An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppressionCancer Immunology, Immunotherapy, 2018
- Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplantAmerican Journal of Hematology, 2017
- Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatmentJournal of Cancer Research and Clinical Oncology, 2016
- Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma modelInternational Journal of Cancer, 2015
- Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromeAmerican Journal of Hematology, 2014
- Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptorsCancer Immunology, Immunotherapy, 2009